Elaine Weiner, MD, assistant professor of psychiatry, College of Maryland Medical System.
Joshua Roffman, MD, assistant professor of psychiatry, Harvard Medical College; director, Mind Genomics Laboratory, Massachusetts Normal Hospital, Boston.
Thomas Milam, MD, chief medical officer, Iris Telehealth; affiliate professor of psychiatry, Virginia Tech Carilion College of Drugs & Analysis Institute.
Present Psychiatry: “Omega-3 fatty acids for psychiatric sickness.”
Scientific Experiences: “The affiliation between neonatal vitamin D standing and threat of schizophrenia.”
Journal of Scientific Endocrinology and Metabolism: “Serum vitamin D ranges in relation to schizophrenia: a scientific overview and meta-analysis of observational research.”
BMC Trials: “Vitamin D supplementation in comparison with placebo in individuals with First Episode psychosis — Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial.”
Cambridge Core: “The results of vitamin and mineral supplementation on signs of schizophrenia: a scientific overview and meta-analysis.”
JAMA Psychiatry: “Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia.”
Molecular Psychiatry: “Biochemical, physiologic, and medical results of L-methylfolate in schizophrenia: A randomized managed trial.”
Cochrane Library: “Vitamin E for antipsychotic‐induced tardive dyskinesia.”
Mind, Conduct and Immunity: “Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot examine.”
BMC Psychiatry: “Scientific and metabolic response to vitamin D plus probiotic in schizophrenia sufferers.”